Please login to the form below

Not currently logged in
Email:
Password:

Alzheimer's

This page shows the latest Alzheimer's news and features for those working in and with pharma, biotech and healthcare.

Six new national standards are launched across UK

Six new national standards are launched across UK

Six new national standards are launched across UK. Will help to improve public involvement in research says ABPI’s Mike Thompson. ... Thompson concluded: “These standards will help ensure patients are at the heart of cutting-edge clinical research

Latest news

  • Celgene bulks up pipeline again with $2.1bn Prothena deal Celgene bulks up pipeline again with $2.1bn Prothena deal

    Celgene bulks up pipeline again with $2.1bn Prothena deal. Acquires candidates with potential in Alzheimer’s, ALS and dementia. ... Its latest deal gives it a preclinical-stage collaboration focused on targets with potential in neurodegenerative

  • Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug Lundbeck signs $1.1bn deal for Prexton and Parkinson’s drug

    movements, and difficulty starting movements known as 'freezing' that can occur between doses of Parkinson’s drugs. ... the failure of Alzheimer’s candidate idalopirdine.

  • FDA approves another home genetic testing service FDA approves another home genetic testing service

    most BRCA mutations that increase an individual’s risk are not detected by this test.”. ... However, the FDA changed its mind last year, allowing the production of 23andMe’s first genetic kit, which tests for gene sequences linked to diseases or

  • Biogen pays $590m for Pfizer cognition drug Biogen pays $590m for Pfizer cognition drug

    When cognition is impaired, you lose the ability to make sense of the world, ”said Michael Ehlers, Biogen’s head of R&D. ... Biogen is making a big R&D play in disease associated with cognitive impairment, and PF-04958242 will slot into its pipeline

  • Another Alzheimer's bust as Merck & Co stops verubecestat study Another Alzheimer's bust as Merck & Co stops verubecestat study

    to late-stage testing in Alzheimer’s, as well as other candidates from the likes of Novartis and Amgen in earlier development. ... Meanwhile, verubecestat’s demise follows a series of recent casualties in the Alzheimer’s pipeline.

More from news
Approximately 93 fully matching, plus 402 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    leukaemia (ALL), Juno's share price had been in the low $20s for several months. ... Under this transaction Takeda gains options to three Denali programmes for neurodegenerative disorders: the ATV: BACE1/Tau and ATV: TREM2 programmes, which are both at

  • The good, the bad and the ugly The good, the bad and the ugly

    Alzheimer’s - where 98% of drugs fail Phase III trials. ... This was largely thanks to Eliquis overtaking Bayer’s Xarelto as the leader in novel oral anticoagulants.

  • Pfizer and IBM's tech-enabled 'Parkinson’s house' Pfizer and IBM's tech-enabled 'Parkinson’s house'

    Our work gives tremendous hope for Parkinson’s and also other cognitive conditions such as Alzheimer’s, if we can broaden the technology in the future.”. ... Since this article was written Pfizer has substantially scaled back its neuroscience R&D

  • Integrating digital biomarkers into precision medicine Integrating digital biomarkers into precision medicine

    Technology’s role in precision medicine is impacting the way researchers and clinicians are able to explain and predict health-related outcomes. ... burden and mild cognitive impairment in potential candidates for an Alzheimer’s study.

  • Righting pharma’s reputational wrongs Righting pharma’s reputational wrongs

    There’s something about the abbreviated name ‘pharma’ - or worse, ‘big pharma’ - that is often uttered with a sense of suspicion. ... Innovation in treatments for conditions such as cancer, Alzheimer’s and rare diseases have the potential to

More from intelligence
Approximately 1 fully matching, plus 35 partially matching documents found.

Latest appointments

  • Cognite strengthens team with two new additions Cognite strengthens team with two new additions

    She has demonstrated real drive and talent across a wide range of disease areas including oncology, MS, diabetes and Alzheimer’s, making her ideally suited to help build successful breakthrough science

  • Metrion Biosciences establishes scientific advisory board Metrion Biosciences establishes scientific advisory board

    The new board will be chaired by Dr Keith McCullagh, Metrion’s non-executive chairman, and its members will include Dr David Reynolds, chief scientific officer at Alzheimer’s Research UK.

  • J&J’s clinical research neuroscience director joins MedAvante J&J’s clinical research neuroscience director joins MedAvante

    Prior to this, he was medical director, global medical affairs for Janssen's Alzheimer's disease immunotherapy unit from June 2011 to May 2013. ... He also brings extensive experience in psychiatry, neurology and dermatology, making him an ideal addition

  • Asceneuron appoints chief medical officer Asceneuron appoints chief medical officer

    He joins the neurodegenerative diseases specialist from Novartis, where he had served a s vice president of its neuroscience development franchise and therapeutic head for neurodegeneration since 2011. ... Alzheimer's disease.

  • UK Dementia Research Institute names director UK Dementia Research Institute names director

    In his new role, Prof De Strooper will work with the institute's founding partners - the Medical Research Council, Alzheimer's Society and Alzheimer's Research UK - to develop new therapeutics

More from appointments
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 4 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GEM Marketing Ltd

GEM, a small but perfectly formed integrated marketing agency servicing the pharmaceutical industry....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics